FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GRANULES Consensus Forecast

No. of reports in last year
6
No. of analysts
3
Average Consensus Forecast
439.17
Consensus Potential
15.26%

GRANULES Price Target Potential

BrokerageTargetPotential
ICICIdirect.com43013.67%
Motilal Oswal44015.64%
Sharekhan47521.85%

GRANULES Targets in FrontPage Forums

17 Users have submitted 18 trade ideas of Rs. 1,452,761.65 for GRANULES
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

GRANULES Ratings

Long term GRANULES rating by FrontPage users
4/5 (3 Ratings)

6 GRANULES share price target reports by brokerages below. See what is analyst's view on GRANULES share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. GRANULES Forum
  3. GRANULES Price Target

GRANULES Share Price Target

GRANULES Share Price Target - Broker Reports - 2021

29-Jul-21
Price @ Call: 371.45
Target: 430
BUY
29-Jul-21
Price @ Call: 371.45
Target: 440
BUY
11-May-21
Price @ Call: 359.9
Target: 475
BUY
12-May-21
Price @ Call: 336.5
Target: 420
BUY

GRANULES Share Price Target - Broker Reports - 2020

21-Oct-20
Price @ Call: 391.65
Target: 460
BUY
12-Sep-20
Price @ Call: 345
Target: 410
BUY
20-Jul-20
Price @ Call: 268.01
Target: 327
BUY
Granules(Inc) is a leading generic player in the Indian pharmaceutical industry, with 2/3rd of its revenue generated from North America and Europe. Granules achieved its highest ever quarterly revenue of Rs.736cr during Q1FY21 with a YoY growth of 24%. The Finished Dosages segment grew by 35% during the quarter as the company successfully launched Colchicine tablets and Butalbital APAP caffeine tablets in the U.S The company reduced its Promoter pledge percentage from 37.6% to 8.7% through the recent buyback process. We expect net profit to grow at a CAGR of 22% over FY20-FY22E on the back of new launches, entry into new geographies as well as its cost optimization measures. Hence we value Granules at 15x FY22E EPS and reiterate a “Buy” rating, with a target price of Rs.327
... Read more
4-Feb-20
Price @ Call: 146.4
Target: 175
BUY
We expect consolidated revenue/PAT to grow at a CAGR of 19%/16% over FY20 -22E given their successful implementation of vertical integration. Management has indicated that they will be launching another 8-9 products in FY21. Considering the lower valuations and improving product profiles, we expect earnings to remain healthy in the long term and upgrade the rating to Buy with a revised target price of Rs175 at 9.5x FY22E EPS.
... Read more
21-Jan-20
Price @ Call: 146.96
Target: 205
BUY
The management is delivering the guidance as of now in 9M with consistent revenue and earnings growth. Promoter have announced that the recent Buyback would lead to meaningful reduction of the pledge share post the closure of buyback (expect less than 5% pledge share from current 37% pledge). EBITDA margins have seen the benefit from improving product mix and operating efficiencies with better capacity utilisations. Also, the launch of own label products in US, new facility commenced at Vizag and Metformin capacity will contribute to the margins. Considering the above consistent improvements, we have increased our earnings by 15% in FY21E and introduce our FY22E along with rolling over to FY22E for valuations. Valuing the stock at 10x FY22E EPS, maintaining BUY rating with revised target price of Rs 205. At CMP of Rs140., GIL is trading at 8.6x FY21E EPS of Rs16.3 and 6.8x FY22E EPS of 20.5.
... Read more
21-Jan-20
Price @ Call: 146.96
Target: 181
BUY
Granules India’s topline continues to be boosted by strong traction in formulations. Its Q3 FY20 sales grew 11% to `7bn. Formulations (FD) grew 23% to Rs 4bn, PFI sales were up 8% to `1bn while APIs declined slightly (3%) to `2bn. The higher contribution from formulations and softening API prices helped to a record 23% EBITDA margin. Adjusted for an impairment charge of Rs 320m on the Biocause JV, PAT shot up 44% to Rs 871m. We expect revenue and PAT CAGRs over FY19-22 of respectively ~17% and ~25%. We maintain our Buy recommendation and raise our target to Rs 181 (earlier Rs 172).
... Read more
22-Jan-20
Price @ Call: 139.65
Target: 165
BUY
We expect earnings CAGR of 26% over FY19-22, led by 19% CAGR in formulation revenue and 490bp EBITDA margin expansion (with an increased share of better-margin products). We continue valuing GRAN at 9x 12M forward earnings to arrive at a TP of INR165 (prior: INR145). Maintain Buy.
... Read more

GRANULES Share Price Target - Broker Reports - 2019

7-Nov-19
Price @ Call: 119.39
Target: 144
BUY
GRAN has done well with 15% CAGR in revenue and an EPS growth of 20% over FY15-19. In last three-four years, GRAN has heavily invested in new capacities and enhance capabilities in finished dosage for longer term growth. We think the current P/E of 8.2x FY21E EPS is at a discount to its intrinsic value, considering strong revenue growth coupled with improving profitability, we believe this valuation gap to narrow down. With focus on deleveraging balance sheet, divestments in joint venture and improving return ratios, we expect stock to trade in its 3-years average one year forward multiple of ~13-14x. We assume earnings CAGR of ~24% over FY19-21E, resulting EPS of Rs12.9/14.4 for FY20/21E respectively.
... Read more
25-Oct-19
Price @ Call: 125.54
Target: 137
ACCUMULATE
Given the success of Granules to integrate its production vertically whereby enabling sales of high margin finished products at a greater quantity, we expect consolidated revenue/PAT to grow at 19%/11% Cover FY20/21E. Considering the lower valuations and improving product profiles, we expect earnings to remain healthy in the long term and change the rating to Accumulate from Buy with a revised target price of Rs137 at 9x FY21E EPS.
... Read more
2-Aug-19
Price @ Call: 92.28
Target: 170
BUY
We maintain BUY on Granules following yet another quarter of robust YoY growth driven by expanded capacities. EBITDA margin at 19.9% was 300bps above estimates, despite a 5% miss on revenue. Our TP is unchanged at Rs 170 (12x FY21E EPS).
... Read more
24-Jun-19
Price @ Call: 95.64
Target: 107
BUY
Company has guided for 20% topline and 25% bottom-line growth for the next three years, primarily driven by ramp-up of utilization levels across the expanded capacities for various key molecules, and new launches in the US market. Overall margins are expected to improve on the back of better product mix.Near-term catalyst: Approval of filed ANDAs, any further reduction in pledge shares, and approval of API plants from key regulators.Key risk: Higher-than-expected pricing pressure, raw material cost inflation and adverse currency movement.We maintain a BUY with a target of Rs. 107
... Read more
14-May-19
Price @ Call: 110.4
Target: 127
BUY
We expect consolidated revenue to grow at 20% CAGR over CY19-21E led by more momentum in the US. We also increase our FY20E revenue and PAT estimates by 10%/18% on improving utilization rates. Considering the lower valuations, management’s focus on improving debt profile and successful passing of raw material costs, we expect earnings to remain healthy in the long term and maintain the Buy rating with a revised target price of Rs127 at 10x FY21E EPS.
... Read more
13-May-19
Price @ Call: 109.63
Target: 150
BUY
We raise our FY20/21 EPS estimate by 2.5%/4.3% to INR10.5/INR12.7 to factor in growth in the formulation business and enhanced API opportunity. We continue valuing GRAN at 13x 12M forward earnings to arrive at a TP of INR150 (prior: INR139). We re-iterate our Buy rating, as growth drivers appear to be in place to deliver 17% earnings CAGR over FY19-21. The improvement in asset turnover, the gradual expansion in margins and the completion of capex phase are likely to drive the return ratios as well over the next 2-3 years.
... Read more
14-May-19
Price @ Call: 110.4
Target: 170
BUY
We maintain BUY on Granules following another strong quarter which was in-line with our estimates. Our TP is unchanged at Rs 170/sh (12x FY21E EPS).
... Read more
2-Feb-19
Price @ Call: 90.11
Target: 160
BUY
31-Jan-19
Price @ Call: 92.08
Target: 140
BUY

GRANULES Share Price Target - Broker Reports - 2018

31-Oct-18
Price @ Call: 97.84
Target: 140
BUY
26-Jul-18
Price @ Call: 97.71
Target: 120
BUY
26-Jul-18
Price @ Call: 93.65
Target: 130
BUY
25-Jul-18
Price @ Call: 91.7
Target: 160
BUY
25-May-18
Price @ Call: 79.46
Target: 115
BUY
30-May-18
Price @ Call: 81.9
Target: 97
BUY
25-May-18
Price @ Call: 85.63
Target: 130
BUY
10-Feb-18
Price @ Call: 117.61
Target: 175
BUY

GRANULES Share Price Target - Broker Reports - 2017

6-Dec-17
Price @ Call: 124.64
Target: 200
BUY
23-Nov-17
Price @ Call: 124.6
Target: 170
BUY
17-Nov-17
Price @ Call: 121.2
Target: 147
BUY
6-Oct-17
Price @ Call: 119.44
Target: 200
BUY
21-Aug-17
Price @ Call: 126.75
Target: 146
BUY
17-Aug-17
Price @ Call: 126.55
Target: 185
BUY
16-May-17
Price @ Call: 144
Target: 167
HOLD
12-May-17
Price @ Call: 143.2
Target: 200
BUY
12-May-17
Price @ Call: 146
Target: 190
BUY
8-Feb-17
Price @ Call: 129
Target: 151
HOLD
31-Jan-17
Price @ Call: 116
Target: 145
BUY

GRANULES Share Price Target - Broker Reports - 2016

9-Dec-16
Price @ Call: 112
Target: 134
BUY
25-Oct-16
Price @ Call: 125
Target: 190
BUY
2-Nov-16
Price @ Call: 122
Target: 156
BUY
26-Oct-16
Price @ Call: 125
Target: 160
BUY
19-Oct-16
Price @ Call: 122.7
Target: 175
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GRANULES Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3398.1
    Upside Target 2391.4
    Upside Target 1385.4
    Pivot378.7
    Downside Target 1372.7
    Downside Target 2366
    Downside Target 3360
  • GRANULES Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3416.93
    Upside Target 2400.97
    Upside Target 1390.18
    Pivot374.22
    Downside Target 1363.43
    Downside Target 2347.47
    Downside Target 3336.68
  • GRANULES Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3385.52
    Upside Target 2363.13
    Upside Target 1347.87
    Pivot325.48
    Downside Target 1310.22
    Downside Target 2287.83
    Downside Target 3272.57
  • GRANULES Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3391.4
    Upside Target 2386.55
    Upside Target 1383.55
    Pivot378.7
    Downside Target 1373.85
    Downside Target 2370.85
    Downside Target 3366
  • GRANULES Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3400.97
    Upside Target 2390.75
    Upside Target 1384.44
    Pivot374.22
    Downside Target 1364
    Downside Target 2357.69
    Downside Target 3347.47
  • GRANULES Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3363.13
    Upside Target 2348.75
    Upside Target 1339.87
    Pivot325.48
    Downside Target 1311.1
    Downside Target 2302.22
    Downside Target 3287.83
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020